Okay, let's tackle this question. The user wants me to create a detailed explanation for the MCQ about HDL being increased by a specific agent. First, I need to recall which drugs are known to increase HDL levels. The core concept here is the pharmacological modulation of HDL cholesterol.

The correct answer is likely to be a fibrates or niacin. Fibrates, like fenofibrate, are known to increase HDL by activating PPAR-alpha, which enhances lipoprotein lipase activity and reduces triglyceride synthesis. Niacin also raises HDL but through different mechanisms, like inhibiting VLDL production.

Now, the options are missing, but common distractors might include statins, which primarily lower LDL and may have a minor effect on HDL. Thiazides are diuretics and not related. Omega-3 fatty acids might increase HDL but not as significantly as fibrates or niacin.

So, the core concept is that HDL is increased by agents that target PPAR-alpha or affect triglyceride metabolism. The correct answer would be a fibrate. The incorrect options would be other drug classes. The clinical pearl is that fibrates are first-line for raising HDL in patients with low levels, especially when combined with hypertriglyceridemia.

I need to structure this into the required sections, making sure each part is concise and fits within the character limit. Also, ensure that the explanation is clear and uses appropriate medical terminology without being too technical. Check for any possible errors in the reasoning, like confusing the effects of different drugs on lipid profiles. Make sure to mention the mechanisms and possible side effects if relevant. Alright, time to put it all together in the specified format.

**Core Concept**
HDL (high-density lipoprotein) is increased by agents that enhance reverse cholesterol transport or activate peroxisome proliferator-activated receptor alpha (PPAR-α). This question tests knowledge of lipid-lowering therapies, specifically their differential effects on HDL levels.

**Why the Correct Answer is Right**
Fibrates (e.g., fenofibrate, gemfibrozil) are PPAR-α agonists that upregulate lipoprotein lipase, increasing HDL synthesis and reducing triglyceride production. They also inhibit hepatic VLDL synthesis, indirectly boosting HDL. This mechanism is distinct from statins, which primarily lower LDL.

**Why Each Wrong Option is Incorrect**
**Option A:** Statins (e.g., atorvastatin) marginally increase HDL but are primarily LDL-lowering agents.
**Option B:** Niacin (vitamin B3) is a potent HDL-raiser but is less commonly used due to side effects like flushing.
**Option C:** Thiazide diuretics (e.g., hydrochlorothiazide) can paradoxically lower HDL in some patients.
**Option D:** Omega-3 fatty acids (e.g., EPA/DHA) modestly increase HDL but are more effective for triglyceride reduction.

**Clinical Pearl / High-Yield Fact**
Fibrates are the first-line therapy for low HDL with hypertriglyceridemia. Remember: **"Fibers raise HDL, statins lower LDL"**—a key distinction for lipid management in exams and practice.

**Correct

✓ Correct Answer: B. Niacin